Back to Awarded Treatment Trials


Awarded Trial: 01-122

Grant ID

01-122

Illness

Bipolar Disorder

Primary Drug/Intervention

Mexiletine

Primary Dosage

600-800 mg

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Schaffer

Sample Size

20

Duration of Study Period for Each Subject

3 weeks

Outcome Measurements

YMRS, CGI

Results

Ten patients with bipolar disorder received mexiletine or placebo adjunctively to other psychotropic medications for three weeks. Although the small sample size precluded accurate statistical comparisons, mexiletine treated patients appeared to have improved scores on the Young Mania Rating Scale (YMRS). There also appeared to be a greater number of "responders" (reduction of YMRS score by 50%) in the mexiletine group at week 1 and week 2.

Publication

Schaffer A, Levitt AJ. Double-blind, placebo-controlled pilot study of mexiletin for acute mania or hypomania (letter). J Clin Psychopharmacol 2005;25:507-508.

Link

http://www.ncbi.nlm.nih.gov/pubmed/16160638

PI Name

Ayal Schaffer

Degree

MD

Center

University of Toronto, Department of Psychiatry

Institution

Sunnybrook & Women's College Health Sciences Centre

Address

2075 Bayview Ave, Room FG 29

City or Town

Toronto

State or Province

Ontario

Zip or Postal Code

M4N 3M5

Country

Canada

Email Address

ayal.schaffer@sw.ca